Transdominant mutant Rev gene therapy

Drug Profile

Transdominant mutant Rev gene therapy

Latest Information Update: 30 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genetic Therapy; Novartis; University of Michigan
  • Class Antivirals; Gene therapies
  • Mechanism of Action Rev gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 18 Nov 1997 Discontinued-Preclinical for HIV infections in France (Unknown route)
  • 26 Feb 1996 An in vitro study has been added
  • 22 Mar 1995 Phase-I clinical trials for HIV infections in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top